GB201913079D0 - Treatment and prevention of cancer using her3 antigen-binding molecules - Google Patents

Treatment and prevention of cancer using her3 antigen-binding molecules

Info

Publication number
GB201913079D0
GB201913079D0 GBGB1913079.8A GB201913079A GB201913079D0 GB 201913079 D0 GB201913079 D0 GB 201913079D0 GB 201913079 A GB201913079 A GB 201913079A GB 201913079 D0 GB201913079 D0 GB 201913079D0
Authority
GB
United Kingdom
Prior art keywords
cancer
prevention
treatment
binding molecules
her3 antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1913079.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hummingbird Bioscience Holdings Ltd
Original Assignee
Hummingbird Bioscience Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hummingbird Bioscience Holdings Ltd filed Critical Hummingbird Bioscience Holdings Ltd
Priority to GBGB1913079.8A priority Critical patent/GB201913079D0/en
Publication of GB201913079D0 publication Critical patent/GB201913079D0/en
Priority to BR112022004474A priority patent/BR112022004474A8/pt
Priority to CA3149853A priority patent/CA3149853A1/en
Priority to KR1020227011181A priority patent/KR20220086554A/ko
Priority to PCT/EP2020/075319 priority patent/WO2021048274A1/en
Priority to JP2022516173A priority patent/JP7708741B2/ja
Priority to EP20780572.2A priority patent/EP3818086B1/en
Priority to CN202080009114.6A priority patent/CN113347994B/zh
Priority to DK20780572.2T priority patent/DK3818086T3/da
Priority to PL20780572T priority patent/PL3818086T3/pl
Priority to CN202211117480.0A priority patent/CN116059347A/zh
Priority to PT207805722T priority patent/PT3818086T/pt
Priority to MX2022002977A priority patent/MX2022002977A/es
Priority to AU2020347473A priority patent/AU2020347473A1/en
Priority to EP21180956.1A priority patent/EP3943509A1/en
Priority to TW109131184A priority patent/TWI883044B/zh
Priority to ES20780572T priority patent/ES2896921T3/es
Priority to US17/153,705 priority patent/US11208498B2/en
Priority to US17/535,313 priority patent/US20220153870A1/en
Priority to JP2025112447A priority patent/JP2025143396A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1913079.8A 2019-09-11 2019-09-11 Treatment and prevention of cancer using her3 antigen-binding molecules Ceased GB201913079D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB1913079.8A GB201913079D0 (en) 2019-09-11 2019-09-11 Treatment and prevention of cancer using her3 antigen-binding molecules
ES20780572T ES2896921T3 (es) 2019-09-11 2020-09-10 Tratamiento y prevención del cáncer usando moléculas de unión al antígeno HER3
DK20780572.2T DK3818086T3 (da) 2019-09-11 2020-09-10 Behandling og forebyggelse af cancer under anvendelse af HER3-antigenbindende molekyler
CN202211117480.0A CN116059347A (zh) 2019-09-11 2020-09-10 使用her3抗原结合分子治疗和预防癌症
KR1020227011181A KR20220086554A (ko) 2019-09-11 2020-09-10 Her3 항원-결합 분자를 사용한 암의 치료 및 예방
PCT/EP2020/075319 WO2021048274A1 (en) 2019-09-11 2020-09-10 Treatment and prevention of cancer using her3 antigen-binding molecules
JP2022516173A JP7708741B2 (ja) 2019-09-11 2020-09-10 Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防
EP20780572.2A EP3818086B1 (en) 2019-09-11 2020-09-10 Treatment and prevention of cancer using her3 antigen-binding molecules
CN202080009114.6A CN113347994B (zh) 2019-09-11 2020-09-10 使用her3抗原结合分子治疗和预防癌症
BR112022004474A BR112022004474A8 (pt) 2019-09-11 2020-09-10 Método de tratamento ou prevenção de um câncer em um sujeito, molécula de ligação ao antígeno para uso neste e uso desta
PL20780572T PL3818086T3 (pl) 2019-09-11 2020-09-10 Leczenie i zapobieganie nowotworom złośliwym z zastosowaniem cząsteczek wiążących antygen HER3
CA3149853A CA3149853A1 (en) 2019-09-11 2020-09-10 Treatment and prevention of cancer using her3 antigen-binding molecules
PT207805722T PT3818086T (pt) 2019-09-11 2020-09-10 Tratamento e prevenção de cancro usando moléculas de ligação ao antigénio her3
MX2022002977A MX2022002977A (es) 2019-09-11 2020-09-10 Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3.
AU2020347473A AU2020347473A1 (en) 2019-09-11 2020-09-10 Treatment and prevention of cancer using HER3 antigen-binding molecules
EP21180956.1A EP3943509A1 (en) 2019-09-11 2020-09-10 Treatment and prevention of cancer using her3 antigen-binding molecules
TW109131184A TWI883044B (zh) 2019-09-11 2020-09-10 使用her3抗原結合分子的癌症之治療及預防
US17/153,705 US11208498B2 (en) 2019-09-11 2021-01-20 Treatment and prevention of cancer using HER3 antigen-binding molecules
US17/535,313 US20220153870A1 (en) 2019-09-11 2021-11-24 Treatment and prevention of cancer using her3 antigen-binding molecules
JP2025112447A JP2025143396A (ja) 2019-09-11 2025-07-02 Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1913079.8A GB201913079D0 (en) 2019-09-11 2019-09-11 Treatment and prevention of cancer using her3 antigen-binding molecules

Publications (1)

Publication Number Publication Date
GB201913079D0 true GB201913079D0 (en) 2019-10-23

Family

ID=68241208

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1913079.8A Ceased GB201913079D0 (en) 2019-09-11 2019-09-11 Treatment and prevention of cancer using her3 antigen-binding molecules

Country Status (16)

Country Link
US (2) US11208498B2 (https=)
EP (2) EP3818086B1 (https=)
JP (2) JP7708741B2 (https=)
KR (1) KR20220086554A (https=)
CN (2) CN116059347A (https=)
AU (1) AU2020347473A1 (https=)
BR (1) BR112022004474A8 (https=)
CA (1) CA3149853A1 (https=)
DK (1) DK3818086T3 (https=)
ES (1) ES2896921T3 (https=)
GB (1) GB201913079D0 (https=)
MX (1) MX2022002977A (https=)
PL (1) PL3818086T3 (https=)
PT (1) PT3818086T (https=)
TW (1) TWI883044B (https=)
WO (1) WO2021048274A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3433273T (pt) 2016-03-25 2022-02-21 Biomunex Pharmaceuticals Moléculas de ligação a cd38 e pd-l1
SG11201809316XA (en) * 2016-04-28 2018-11-29 Biomunex Pharmaceuticals Bispecific antibodies targeting egfr and her2
KR20240125061A (ko) 2017-03-27 2024-08-19 바이오뮤넥스 파마슈티컬스 안정적인 다중특이적 항체
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
CN114790462B (zh) * 2021-01-25 2023-10-31 中国医学科学院血液病医院(中国医学科学院血液学研究所) 靶向bcma的嵌合抗原受体及其应用
CN112961865B (zh) * 2021-02-22 2023-06-02 广西大学 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用
EP4304636A1 (en) * 2021-03-11 2024-01-17 Elevation Oncology, Inc. Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions
TW202313987A (zh) * 2021-06-03 2023-04-01 荷蘭商美勒斯公司 用於測定nrg1融合多核苷酸的液態檢體測定法
JP2024523001A (ja) * 2021-06-03 2024-06-25 メルス ナムローゼ フェンノートシャップ 新たなｎｒｇ１融合体、融合接合部及びそれらを検出するための方法
GB202108449D0 (en) 2021-06-14 2021-07-28 Hummingbird Bioscience Holdings Pte Ltd Cells expressing her3 antigen-binding molecules
US20250136712A1 (en) 2021-08-13 2025-05-01 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3 antigen-binding molecules
JP2024536719A (ja) * 2021-09-03 2024-10-08 キャンサー・リサーチ・テクノロジー・リミテッド Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防
CN116333118B (zh) * 2021-12-16 2024-04-19 徕特康(苏州)生物制药有限公司 抗表皮生长因子受体抗体及其制备方法和用途
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
WO2024121163A1 (en) 2022-12-06 2024-06-13 Cancer Research Technology Limited Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers
CN120417924A (zh) 2022-12-07 2025-08-01 蜂鸟生物科技私人有限公司 治疗和预防癌症的组合疗法
WO2024147097A1 (en) 2023-01-03 2024-07-11 Hummingbird Bioscience Pte. Ltd. Her3-binding antibody-drug conjugate
EP4687972A1 (en) 2023-04-06 2026-02-11 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3 antigen-binding molecules
KR20260022498A (ko) 2023-04-14 2026-02-19 허밍버드 바이오사이언스 피티이. 엘티디. 암의 치료 및 예방을 위한 조합물
WO2025057173A2 (en) * 2023-09-14 2025-03-20 B.G. Negev Technologies And Applications Ltd. Ligand-based chimeric antigen receptors and uses thereof
WO2025056781A1 (en) 2023-09-15 2025-03-20 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3-binding molecules

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
MY152068A (en) * 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
EP2571901B1 (en) * 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
CN104105709A (zh) * 2011-12-05 2014-10-15 诺华股份有限公司 抗her3的结构域ii的表皮生长因子受体3(her3)抗体
US20130259867A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
EP2961773B1 (en) 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
WO2014182970A1 (en) * 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
EP3085781A1 (en) 2013-12-19 2016-10-26 National Cancer Center Novel fusion gene as factor responsible for stomach cancer
WO2016059602A2 (en) * 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
JP6180663B2 (ja) * 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
EP3091033A1 (en) * 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
EP3679063A4 (en) 2017-09-08 2021-06-02 The Regents of The University of Colorado, A Body Corporate COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
WO2019185164A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules

Also Published As

Publication number Publication date
KR20220086554A (ko) 2022-06-23
TWI883044B (zh) 2025-05-11
PT3818086T (pt) 2021-10-26
CN116059347A (zh) 2023-05-05
JP7708741B2 (ja) 2025-07-15
PL3818086T3 (pl) 2022-03-14
US20210155712A1 (en) 2021-05-27
US11208498B2 (en) 2021-12-28
CN113347994B (zh) 2022-09-23
BR112022004474A2 (pt) 2022-06-21
CA3149853A1 (en) 2021-03-18
DK3818086T3 (da) 2021-10-04
TW202123926A (zh) 2021-07-01
EP3943509A1 (en) 2022-01-26
AU2020347473A1 (en) 2022-03-31
MX2022002977A (es) 2022-07-12
BR112022004474A8 (pt) 2023-01-17
ES2896921T3 (es) 2022-02-28
JP2025143396A (ja) 2025-10-01
EP3818086B1 (en) 2021-08-04
WO2021048274A1 (en) 2021-03-18
JP2022548057A (ja) 2022-11-16
EP3818086A1 (en) 2021-05-12
US20220153870A1 (en) 2022-05-19
CN113347994A (zh) 2021-09-03

Similar Documents

Publication Publication Date Title
PT3818086T (pt) Tratamento e prevenção de cancro usando moléculas de ligação ao antigénio her3
IL313807A (en) Claudin 18 antibodies and methods for cancer treatment
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
IL279347A (en) Gremlin-1 antagonist for cancer prevention and treatment
EP3270966A4 (en) Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer
IL277981A (en) Cancer treatment methods
SG11202011117VA (en) Treatment of cancer
IL272669A (en) Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer
IL286297A (en) Minimal residual cancer treatment methods
SG11202010793UA (en) Methods of treating cancer
IL281600B2 (en) Cancer treatment methods
IL276203A (en) Compounds and methods for treating cancer
GB201919428D0 (en) Immunotherapeutic treatment of cancer
SG11202109097UA (en) Materials and methods for enhanced treatment and prevention of biofilms
IL289811A (en) A method for treating cancer
IL279591A (en) Cancer treatment methods using combination therapy
SG11202107017TA (en) Methods of treating cancer
IL267613A (en) Pancreatic cancer treatment
IL287538A (en) Preparations and methods for the treatment of cancer
SI3630112T1 (sl) Kombinacija regorafeniba in nivolumaba za zdravljenje raka
IL288178A (en) Combined gmci and ddri treatment for cancer
GB202107994D0 (en) Treatment of cancer
IL276905A (en) Treatment and prevention of preeclampsia
GB201918692D0 (en) Treatment and prognosis of pancreatic cancer
GB201820098D0 (en) Methods of cancer treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)